Zymar 5 Ml Tablets<\/strong> contains gatifloxacin ophthalmic solution 0.3%<\/strong> and is positioned as a fluoroquinolone ophthalmic antibiotic used under clinical supervision. In practical terms, that means the medicine is selected because its pharmacology maps to a specific therapeutic need rather than because it is a general symptom reliever. This page summarizes the product in a way that is useful for patients, caregivers, and healthcare teams while staying focused on the core facts needed for safe use.<\/p>\n The brand name may be the first thing a patient sees, but safe use depends on the full clinical profile: ingredient, strength, dosage form, manufacturer, and intended indication. For that reason, the sections below keep the explanation tied to the drug class, the expected clinical effect, and the precautions that matter most in routine practice.<\/p>\n Zymar 5 Ml Tablets is a ophthalmic solution manufactured by Allergan<\/strong>. It is used in settings where the underlying condition and the expected benefit are well established. In everyday prescribing, the brand may be chosen for a mix of reasons such as clinician familiarity, formulation, dose convenience, or the need to match an established treatment pathway. Because pharmaceutical products must be matched to the right diagnosis, this description is informational and should not replace a clinician\u2019s instructions or the official label.<\/p>\n Patients should not assume that a familiar brand name means the same thing as another medicine with a similar sound. The strength, route of administration, and therapeutic class are what determine how the product is used and what monitoring may be necessary.<\/p>\n Zymar 5 Ml Tablets acts through gatifloxacin ophthalmic solution 0.3%, a fluoroquinolone antibacterial that inhibits bacterial DNA gyrase and topoisomerase IV. That interrupts DNA replication and repair, which suppresses bacterial growth and helps resolve susceptible ocular infection.<\/p>\n At a practical level, this mechanism explains why the medicine may be chosen when a clinician wants to target infection control, pressure reduction, or bone formation depending on the therapeutic class. The exact clinical response depends on diagnosis, dose, duration, and patient-specific factors. The class effect also shapes follow-up: antibiotics are assessed for symptom resolution and resistance risk, glaucoma therapies for pressure control, and anabolic bone agents for longer-term fracture prevention and laboratory monitoring.<\/p>\n That class-specific lens matters. Two medicines may both be prescription products, but their mechanisms can sit in entirely different parts of the disease process. One may kill bacteria directly, another may improve fluid drainage in the eye, and another may stimulate bone formation. The correct explanation depends on the pharmacology, not on the dosage form alone.<\/p>\n Zymar 5 Ml Tablets is typically used for bacterial conjunctivitis. Prescribers may use the medicine within approved labeling or accepted clinical practice, depending on the market and the patient\u2019s needs.<\/p>\n For a patient, the indication is the clearest signal of why the medication exists. Antibiotics are meant for susceptible bacterial infections and should not be repurposed for viral illness. Eye-pressure medicines are selected to protect vision over time rather than to create immediate symptom relief. Bone-building therapy is used for patients whose fracture risk is high enough that a stimulant to new bone formation has a favorable benefit-risk balance.<\/p>\n General administration guidance: one drop up to four times daily after the initial intensive phase, following the prescriber or label instructions. Patients should follow the dose, timing, and duration prescribed by their clinician and should not change the schedule on their own.<\/p>\n \u6295\u4e0e\u306f\u5b89\u5168\u306a\u4f7f\u7528\u304c\u6210\u529f\u3059\u308b\u304b\u5931\u6557\u3059\u308b\u304b\u3092\u6c7a\u5b9a\u3059\u308b\u91cd\u8981\u306a\u8981\u7d20\u3067\u3059\u3002\u7d4c\u53e3\u6297\u751f\u7269\u8cea\u306f\u3001\u5168\u91cf\u3092\u5b8c\u4e86\u3057\u305f\u5834\u5408\u306b\u6700\u3082\u52b9\u679c\u7684\u306b\u4f5c\u7528\u3057\u307e\u3059\u3002\u773c\u79d1\u7528\u88fd\u5264\u306f\u3001\u70b9\u773c\u306e\u6b63\u78ba\u306a\u6295\u4e0e\u3001\u6c5a\u67d3\u3092\u9632\u3050\u305f\u3081\u306e\u5148\u7aef\u306e\u6e05\u6f54\u3055\u3001\u4f59\u5206\u306a\u70b9\u6ef4\u3092\u62ed\u304d\u53d6\u308b\u3053\u3068\u3001\u305d\u3057\u3066\u4ed6\u306e\u70b9\u773c\u85ac\u3092\u8ffd\u52a0\u3059\u308b\u524d\u306b\u5f85\u6a5f\u3059\u308b\u3053\u3068\u306b\u3088\u308a\u3001\u6700\u9069\u306b\u6a5f\u80fd\u3057\u307e\u3059\u3002\u6ce8\u5c04\u5264\u306f\u3001\u4fdd\u5b58\u6761\u4ef6\u3001\u7121\u83cc\u7684\u53d6\u308a\u6271\u3044\u3001\u51e6\u65b9\u533b\u307e\u305f\u306f\u770b\u8b77\u5e2b\u304c\u6307\u5c0e\u3057\u305f\u6295\u4e0e\u6280\u8853\u306b\u7d30\u5fc3\u306e\u6ce8\u610f\u3092\u6255\u3046\u5fc5\u8981\u304c\u3042\u308a\u307e\u3059\u3002<\/p>\n \u526f\u4f5c\u7528\u306f\u88fd\u5264\u30af\u30e9\u30b9\u306b\u3088\u3063\u3066\u7570\u306a\u308a\u307e\u3059\u3002\u6297\u751f\u7269\u8cea\u306f\u80c3\u8178\u306e\u4e0d\u5feb\u611f\u3084\u767a\u75b9\u3092\u5f15\u304d\u8d77\u3053\u3059\u3053\u3068\u304c\u3042\u308a\u307e\u3059\u3002\u7dd1\u5185\u969c\u7528\u70b9\u773c\u85ac\u306f\u773c\u306e\u8d64\u307f\u3084\u307e\u3076\u305f\u306e\u5909\u5316\u3092\u5f15\u304d\u8d77\u3053\u3059\u3053\u3068\u304c\u3042\u308a\u307e\u3059\u3002\u6297\u83cc\u6027\u773c\u79d1\u70b9\u773c\u85ac\u306f\u523a\u6fc0\u3092\u5f15\u304d\u8d77\u3053\u3059\u3053\u3068\u304c\u3042\u308a\u307e\u3059\u3002\u9aa8\u5438\u53ce\u6291\u5236\u5264\u306f\u3001\u30ab\u30eb\u30b7\u30a6\u30e0\u95a2\u9023\u306e\u526f\u4f5c\u7528\u3084\u305d\u306e\u4ed6\u306e\u6ce8\u610f\u4e8b\u9805\u306e\u30e2\u30cb\u30bf\u30ea\u30f3\u30b0\u3092\u5fc5\u8981\u3068\u3059\u308b\u3053\u3068\u304c\u3042\u308a\u307e\u3059\u3002\u30a2\u30ec\u30eb\u30ae\u30fc\u3001\u598a\u5a20\u3001\u6388\u4e73\u3001\u814e\u6a5f\u80fd\u4f4e\u4e0b\u3001\u8907\u96d1\u306a\u4f75\u5b58\u75be\u60a3\u304c\u3042\u308b\u60a3\u8005\u306f\u3001\u4f7f\u7528\u524d\u306b\u533b\u7642\u6a5f\u95a2\u306b\u76f8\u8ac7\u3057\u3066\u304f\u3060\u3055\u3044\u3002<\/p>\n \u30af\u30e9\u30b9\u3054\u3068\u306e\u6ce8\u610f\u4e8b\u9805\u306f\u91cd\u8981\u3067\u3059\u3002\u6297\u83cc\u85ac\u306e\u5834\u5408\u3001\u60a3\u8005\u306f\u30a2\u30ec\u30eb\u30ae\u30fc\u53cd\u5fdc\u3001\u4e0b\u75e2\u3001\u307e\u305f\u306f\u6cbb\u7642\u304c\u4e0d\u5341\u5206\u3067\u3042\u308b\u5146\u5019\uff08\u8010\u6027\u83cc\u304c\u51fa\u73fe\u3057\u3066\u3044\u308b\u304b\u3001\u8a3a\u65ad\u304c\u8aa4\u3063\u3066\u3044\u308b\u53ef\u80fd\u6027\u304c\u3042\u308b\uff09\u306b\u6ce8\u610f\u3057\u3066\u304f\u3060\u3055\u3044\u3002\u7dd1\u5185\u969c\u6cbb\u7642\u3067\u306f\u3001\u9577\u671f\u7684\u306a\u670d\u7528\u306e\u91cd\u8981\u6027\u3092\u5f37\u8abf\u3057\u3001\u305f\u307e\u306b\u4f7f\u7528\u3059\u308b\u3060\u3051\u3067\u306f\u4e0d\u5341\u5206\u3067\u3042\u308b\u3053\u3068\u3092\u60a3\u8005\u306b\u4f1d\u3048\u307e\u3059\u3002\u307e\u305f\u3001\u8272\u7d20\u6c88\u7740\u3084\u307e\u3064\u3052\u306e\u5909\u5316\u304c\u30d7\u30ed\u30b9\u30bf\u30b0\u30e9\u30f3\u30b8\u30f3\u985e\u4f3c\u85ac\u3067\u8d77\u3053\u308b\u3053\u3068\u304c\u3042\u308b\u3053\u3068\u3092\u8aac\u660e\u3057\u307e\u3059\u3002\u30c6\u30ea\u30d1\u30e9\u30c1\u30c9\u7cfb\u85ac\u5264\u306e\u5834\u5408\u3001\u9aa8\u306e\u5065\u5eb7\u5168\u4f53\u306e\u8a08\u753b\u304c\u91cd\u8981\u3067\u3059\u3002\u30ab\u30eb\u30b7\u30a6\u30e0\u30d0\u30e9\u30f3\u30b9\u3001\u9aa8\u6298\u30ea\u30b9\u30af\u3001\u6cbb\u7642\u671f\u9593\u3001\u30d5\u30a9\u30ed\u30fc\u30a2\u30c3\u30d7\u304c\u6700\u7d42\u7684\u306a\u6cbb\u7642\u6210\u7e3e\u306b\u5f71\u97ff\u3092\u4e0e\u3048\u307e\u3059\u3002<\/p>\n \u6df1\u523b\u306a\u30a2\u30ec\u30eb\u30ae\u30fc\u53cd\u5fdc\u3001\u6301\u7d9a\u7684\u306a\u60aa\u5316\u3001\u8996\u529b\u306e\u6025\u6fc0\u306a\u5909\u5316\u3001\u816b\u308c\u3001\u5f37\u3044\u3081\u307e\u3044\u3001\u307e\u305f\u306f\u91cd\u5ea6\u306e\u4e0d\u8010\u75c7\u306e\u5146\u5019\u304c\u73fe\u308c\u305f\u5834\u5408\u306f\u3001\u3059\u3050\u306b\u533b\u7642\u6a5f\u95a2\u306b\u9023\u7d61\u3057\u3066\u304f\u3060\u3055\u3044\u3002\u3069\u306e\u88fd\u5264\u30ab\u30c6\u30b4\u30ea\u306b\u304a\u3044\u3066\u3082\u3001\u30e9\u30d9\u30eb\u3067\u8a18\u8f09\u3055\u308c\u3066\u3044\u308b\u4e00\u822c\u7684\u306a\u526f\u4f5c\u7528\u3088\u308a\u3082\u5f37\u3044\u3001\u6301\u7d9a\u7684\u3001\u307e\u305f\u306f\u4e0d\u9069\u5207\u306a\u65b0\u3057\u3044\u526f\u4f5c\u7528\u306f\u3001\u76f4\u3061\u306b\u533b\u7642\u6a5f\u95a2\u306b\u5831\u544a\u3057\u3066\u304f\u3060\u3055\u3044\u3002<\/p>\n \u516c\u5f0f\u30e9\u30d9\u30eb\u306b\u5f93\u3063\u3066\u4fdd\u7ba1\u3057\u3066\u304f\u3060\u3055\u3044\u3002\u4e00\u90e8\u306e\u6ce8\u5c04\u5264\u306f\u51b7\u8535\u304c\u5fc5\u8981\u3067\u3059\u3002\u773c\u79d1\u7528\u70b9\u773c\u85ac\u306f\u6e05\u6f54\u306b\u4fdd\u3061\u3001\u30ad\u30e3\u30c3\u30d7\u3092\u9589\u3081\u3001\u6c5a\u67d3\u3092\u9632\u3050\u5fc5\u8981\u304c\u3042\u308a\u307e\u3059\u3002\u7d4c\u53e3\u9320\u5264\u306f\u4e7e\u71e5\u3057\u305f\u5834\u6240\u306b\u4fdd\u7ba1\u3057\u3001\u71b1\u3084\u76f4\u5c04\u5149\u304b\u3089\u9060\u3056\u3051\u3066\u304f\u3060\u3055\u3044\u3002\u4fdd\u7ba1\u6761\u4ef6\u3092\u6295\u4e0e\u524d\u306b\u78ba\u8a8d\u3059\u308b\u3053\u3068\u304c\u91cd\u8981\u3067\u3059\u3002\u6b63\u3057\u3044\u85ac\u5264\u3067\u3082\u3001\u6e29\u3081\u3001\u51b7\u51cd\u3001\u8aa4\u3063\u3066\u958b\u5c01\u3001\u307e\u305f\u306f\u6709\u52b9\u671f\u9650\u5207\u308c\u306e\u5834\u5408\u306f\u52b9\u679c\u304c\u5931\u308f\u308c\u308b\u3053\u3068\u304c\u3042\u308a\u307e\u3059\u3002<\/p>\n \u6b63\u78ba\u306a\u30e9\u30d9\u30eb\u304c\u533b\u5e2b\u3084\u85ac\u5264\u5e2b\u306b\u63d0\u4f9b\u3055\u308c\u3066\u3044\u308b\u5834\u5408\u3001\u305d\u306e\u30e9\u30d9\u30eb\u304c\u4e00\u822c\u7684\u306a\u6307\u5c0e\u3088\u308a\u3082\u512a\u5148\u3055\u308c\u307e\u3059\u3002\u30de\u30eb\u30c1\u30c9\u30fc\u30ba\u5bb9\u5668\u306e\u5834\u5408\u3001\u958b\u5c01\u5f8c\u3069\u306e\u7a0b\u5ea6\u4f7f\u7528\u53ef\u80fd\u304b\u3001\u305d\u3057\u3066\u4f7f\u7528\u671f\u9650\u304c\u3044\u3064\u304b\u3092\u60a3\u8005\u306b\u4f1d\u3048\u308b\u5fc5\u8981\u304c\u3042\u308a\u307e\u3059\u3002<\/p>\n Zymar 5 Ml Tablets: Clinical Profile, Uses, Dosage, and Safety Zymar 5 Ml Tablets contains gatifloxacin ophtha […]<\/p>\n","protected":false},"featured_media":0,"comment_status":"open","ping_status":"closed","template":"","meta":[],"product_brand":[10305],"product_cat":[16265],"product_tag":[11761,11800],"igm_manufacturer":[],"class_list":["post-138980","product","type-product","status-publish","product_brand-allergan","product_cat-mens-health-wellness","product_tag-eye-drops","product_tag-vial-bottle","pa_brand-name-zymar","pa_molecule-gatifloxacin","first","instock","sale","shipping-taxable","purchasable","product-type-simple"],"_links":{"self":[{"href":"https:\/\/indogenmed.org\/ja\/wp-json\/wp\/v2\/product\/138980","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/indogenmed.org\/ja\/wp-json\/wp\/v2\/product"}],"about":[{"href":"https:\/\/indogenmed.org\/ja\/wp-json\/wp\/v2\/types\/product"}],"replies":[{"embeddable":true,"href":"https:\/\/indogenmed.org\/ja\/wp-json\/wp\/v2\/comments?post=138980"}],"wp:attachment":[{"href":"https:\/\/indogenmed.org\/ja\/wp-json\/wp\/v2\/media?parent=138980"}],"wp:term":[{"taxonomy":"product_brand","embeddable":true,"href":"https:\/\/indogenmed.org\/ja\/wp-json\/wp\/v2\/product_brand?post=138980"},{"taxonomy":"product_cat","embeddable":true,"href":"https:\/\/indogenmed.org\/ja\/wp-json\/wp\/v2\/product_cat?post=138980"},{"taxonomy":"product_tag","embeddable":true,"href":"https:\/\/indogenmed.org\/ja\/wp-json\/wp\/v2\/product_tag?post=138980"},{"taxonomy":"igm_manufacturer","embeddable":true,"href":"https:\/\/indogenmed.org\/ja\/wp-json\/wp\/v2\/igm_manufacturer?post=138980"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}Introduction<\/h2>\n
Product Overview \/ Clinical Profile<\/h2>\n
\n
Mechanism of Action<\/h2>\n
Therapeutic Indications<\/h2>\n
Dosage and Administration<\/h2>\n
\n
\u5b89\u5168\u6027\u30d7\u30ed\u30d5\u30a1\u30a4\u30eb\u3068\u6ce8\u610f\u4e8b\u9805<\/h2>\n
\u4fdd\u7ba1\u3068\u53d6\u308a\u6271\u3044<\/h2>\n